Stockreport

Bristol-Myers Squibb Provides Update on the Ongoing Regulatory Review of Opdivo Plus Low-Dose Yervoy in First-Line Lung Cancer Patients with Tumor Mutational Burden =10 mut/Mb

Bristol-Myers Squibb Company  (BMY) 
Last bristol-myers squibb company earnings: 2/6 07:05 am Check Earnings Report
US:NYSE Investor Relations: bms.com/investors.html
PDF New analysis submitted to U.S. Food and Drug Administration (FDA) constitutes a major amendment to the Company’s supplemental Biologics License Applicati [Read more]